Patterns of Inclisiran Use in the Real World: An Analysis of US Databases
Completed
- Conditions
- Atherosclerotic Cardiovascular DiseaseFamilial Hypercholesterolemia
- First Posted Date
- 2025-06-17
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 37688
- Registration Number
- NCT07023445
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
Phase 1
Not yet recruiting
- Conditions
- Small Cell Lung CarcinomaLarge Cell Neuroendocrine Carcinoma of the LungNeuroendocrine Prostate CancerGastroenteropancreatic Neuroendocrine Carcinoma
- Interventions
- Drug: 225Ac-ETN029Drug: 111In-ETN029
- First Posted Date
- 2025-06-05
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 116
- Registration Number
- NCT07006727
Managed Access Programs for TQJ230, Pelacarsen
- Conditions
- Atherosclerotic Cardiovascular Disease, ASCVD
- First Posted Date
- 2025-06-03
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT07000695
EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)
Phase 2
Not yet recruiting
- Conditions
- PIK3CA-related Overgrowth Spectrum (PROS)
- Interventions
- First Posted Date
- 2025-05-30
- Last Posted Date
- 2025-05-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 104
- Registration Number
- NCT06997588
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN
Phase 3
Not yet recruiting
- Conditions
- Primary Immunoglobulin A Nephropathy (IgAN)
- Interventions
- First Posted Date
- 2025-05-29
- Last Posted Date
- 2025-05-29
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT06994845
Real-world Outcomes of Aplastic Anemia Patients Treated With Eltrombopag: A Medical Claims Database Study
Completed
- Conditions
- Anemia, Aplastic
- First Posted Date
- 2025-05-28
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 2517
- Registration Number
- NCT06991894
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
A Study to Compare Digital Disease Monitoring of Patients With csU (Telemedicine to Face-to-Face Visits) in Germany
Active, not recruiting
- Conditions
- Chronic Spontaneous Urticaria
- First Posted Date
- 2025-05-28
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 116
- Registration Number
- NCT06991608
- Locations
- 🇩🇪
Novartis Investigative Site, Selters, Germany
An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Phase 2
Recruiting
- Conditions
- Metastatic Hormone-sensitive Prostate Cancer
- Interventions
- First Posted Date
- 2025-05-28
- Last Posted Date
- 2025-06-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 150
- Registration Number
- NCT06991556
- Locations
- 🇺🇸
Urology Cancer Center PC, Omaha, Nebraska, United States
Inclisiran (Leqvio®) in Patients With Atherosclerotic Vascular Disease and/or Heterozygous Familial Hypercholesterolemia Treated in Spain: the INSPIRE Study
Recruiting
- Conditions
- Atherosclerotic Vascular DiseaseHeterozygous Familial Hypercholesterolemia
- First Posted Date
- 2025-05-06
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 200
- Registration Number
- NCT06958315
- Locations
- 🇪🇸
Novartis Investigative Site, Logrono, La Rioja, Spain
A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US
Recruiting
- Conditions
- Immunoglobulin A Nephropathy
- First Posted Date
- 2025-04-30
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 300
- Registration Number
- NCT06952426
- Locations
- 🇺🇸
Novartis Investigational site, Boston, Massachusetts, United States